The curtain on the fifth batch of centralized procurement of drugs with a large amount has begun, and policy efforts have continued to deepen

On May 8, 2021, the National Organization Drug Joint Procurement Office issued the "Notice on Carrying out the Fifth Batch of National Organization Drug Centralized Procurement of Drug Information Collection", requiring relevant units to organize information declaration work.

Due to the huge impact of centralized procurement on the pharmaceutical industry, there have been endless discussions about "whether centralized procurement can be sustained".

In the fifth batch of centralized procurement lists, the most interesting is the inclusion of many injections, including drugs such as ceftriaxone and levofloxacin, which are widely used clinically.

In the early stage of mass collection, the selected varieties were mainly oral tablets, because of their reliable quality, strong safety, and a more mature consistency (bioequivalence) evaluation method to assist in the selection of varieties.

With the advancement of the evaluation of the consistency of the quality and efficacy of injections, the centralized procurement of injection drugs has gradually begun.

Of course, with the overall advancement of the centralized procurement work, longer-term and comprehensive institutional arrangements also need to have overall consideration and appropriate design.

On the other hand, with the advancement of centralized procurement, the industry concentration of my country's pharmaceutical market will continue to increase.

Centralized procurement of pharmaceuticals is a complex and difficult task, involving a wide range of interests and great social impact, and has also been questioned by many.